Study of APD421 as PONV Treatment (Prior Prophylaxis)

NCT ID: NCT02646566

Last Updated: 2019-01-22

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 705 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-03-31
• Study Completion Date: 2017-01-31

Brief Summary

Double-blind, randomised, parallel-group, placebo-controlled, adaptive, seamless, dose-selecting study to compare the efficacy of APD421 to placebo as treatment of established PONV, in patients who have had prior PONV prophylaxis.

Conditions

Postoperative Nausea and Vomiting

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

APD421 standard

Single (standard) dose IV APD421

Group Type: EXPERIMENTAL

APD421

Intervention Type: DRUG

APD421 high

Single (high) dose IV APD421

Group Type: EXPERIMENTAL

APD421

Intervention Type: DRUG

Placebo

Single IV placebo

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Interventions

APD421

Intervention Type: DRUG

Placebo

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Male or female patients ≥ 18 years of age
• Provision of written informed consent
• Patients scheduled to undergo elective surgery (open or laparoscopic technique) under general anaesthesia (other than total intravenous anaesthesia with propofol) expected to last at least one hour from induction of anaesthesia to extubation
• Patients judged by the investigator to have a moderate or high risk of experiencing PONV. In forming this judgment, investigators should pay particular attention to risk factors such as a past history of PONV and/or motion sickness; habitual non-smoking status; female sex; and likely use of opioid analgesia post-operatively.
• For females of child-bearing potential: ability and willingness to use a highly effective form of contraception (as defined in ICH M3 guidance, e.g., abstinence from sexual intercourse, surgical sterilisation (of subject or partner), combined oral contraceptive pill, a double-barrier method of contraception such as either an intra-uterine device (IUD) or an occlusive cap with spermicide, in conjunction with partner's use of a condom, or any other method or combination of methods with a failure rate generally considered to be <1% per year) between the date of screening and at least 48 hours after administration of study drug
• In order to be eligible for randomisation, subjects must also:

(i) have experienced a first episode of PONV not more than 24 hours after the end of their operation (wound closure) and prior to discharge from hospital ("qualifying PONV episode"), for which they have not already received any anti-emetic treatment; and (ii) not have received any dopamine-antagonist agent likely to prevent or treat nausea or vomiting (given as prophylaxis or otherwise) in the period from 24 hours prior to the start of their operation up to the time of the qualifying PONV episode.

Exclusion Criteria

• Patients scheduled to undergo transplant surgery or any surgery where post-operative emesis may pose a significant danger to the patient
• Patients planned to receive only a local anaesthetic and/or regional neuraxial (intrathecal or epidural) block
• Patients who have received APD421 active ingredient for any indication within the last 2 weeks
• Patients who are allergic to APD421 active ingredient or any of the excipients of APD421
• Patients with a significant, ongoing history of vestibular disease or dizziness
• Patients with a known prolactin-dependent tumour (e.g. pituitary gland prolactinoma or breast cancer) or phaeochromocytoma.
• Patients with documented or suspected alcohol or substance abuse within the past 6 months.
• Patients with direct or indirect evidence of clinically significant hypokalaemia, such as a serum potassium level < 3.0 mmol/L.
• Patients who have received in the post-operative period, and prior to receiving study drug, any medication with a substantial risk of inducing torsades de pointes, including Class Ia antiarrhythmic agents such as quinidine, disopyramide, procainamide; Class III antiarrhythmic agents such as amiodarone and sotalol; and other medications such as bepridil, cisapride, thioridazine, methadone, IV erythromycin, IV vincamine, halofantrine, pentamidine, sparfloxacin, etc.
• Patients who have a documented, clinically significant cardiac arrhythmia or congenital long QT syndrome.
• Patients who are pregnant or breast feeding.
• Patients being treated with levodopa.
• Patients diagnosed with Parkinson's disease.
• Patients who have received emetogenic anti-cancer chemotherapy in the previous 4 weeks.
• Patients with a history of epilepsy.
• Any other concurrent disease or illness that, in the opinion of the investigator makes the patient unsuitable for the study.
• Patients who have previously participated in this study or who have participated in another interventional clinical study involving pharmacological therapy within the previous 28 days (or longer exclusion period, if required by national or local regulations).
• Where local laws/regulations require: patients under legal protection.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Acacia Pharma Ltd

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Gabriel Fox, MB BChir

Role: STUDY_DIRECTOR

Acacia Pharma Ltd

Locations

Jackson Memorial Hospital

Miami, Florida, United States

Duke University Medical Center

Durham, North Carolina, United States

Wake Forest University School of Medicine

Winston-Salem, North Carolina, United States

Ohio State University

Columbus, Ohio, United States

CHU de Hautepierre

Strasbourg, , France

HELIOS Klinikum Aue

Aue, , Germany

Universität Heidelberg

Heidelberg, , Germany

Philipps University

Marburg, , Germany

Countries

United States; France; Germany

Other Identifiers

DP10019

Identifier Type: -

Identifier Source: org_study_id